PA
FOLD

PharVision Advisers’s Amicus Therapeutics FOLD Stock Holding History

PharVision Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,998
Closed -$94.5K – 791
2025
Q3 		$94.5K Buy
+11,998
New +$85.4K 0.05% 628

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PharVision Advisers's FOLD Position: Q4 2025 in Review

PharVision Advisers sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 11,998 shares — an estimated $94.5K sold.

PharVision Advisers first reported a position in FOLD in Q3 2025 and held it in 1 quarter. The position peaked at $94.5K in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • PharVision Advisers reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 11,998 Amicus Therapeutics shares in Q4 2025, an estimated $94.5K.
  • PharVision Advisers first reported a position in Amicus Therapeutics in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Amicus Therapeutics position peaked at $94.5K in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.